Reinforcing the hypothesis that XPO7 could be a novel tumor suppressor, PRAD patients with heterozygous or homozygous deletion of XPO7 had a significantly worse progression-free survival than their wt counterparts (Fig. 7B). The gene discussed is XPO7; the disease is prostate adenocarcinoma.